PRIMARY STUDY
Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose.
Key Findings: It is concluded that the dopamine partial agonist action of cannabidiol may account for its clinical antipsychotic effects.
Type of Study: Laboratory Study
Study Result: Positive
Research Location(s): Canada
Year of Pub: 2016
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype III
Ligands Studied: Dopamine
Route of Administration: In vitro
Citation: Seeman P. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Transl Psychiatry. 2016; 6:e920. doi: 10.1038/tp.2016.195
Authors: Seeman P
